A Study of ADXS-NEO Expressing Personalized Tumor Antigens (NEO)
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Sponsor: Advaxis, Inc.
Terminated
Business decision
Other terminated trials from Advaxis, Inc.
- Cancer · Phase PHASE1/PHASE2 · Nov 2020
- Advanced Cervical Cancer · Phase PHASE3 · Jul 2019
- Cervical Intraepithelial Neoplasia · Phase PHASE2 · Apr 2016
- HPV-16 +ve Oropharyngeal Carcinoma · Phase PHASE1 · Nov 2014
More terminations from Advaxis, Inc.
This PHASE1 trial investigates Colon Cancer Metastatic and Head and Neck Cancer Metastatic and is currently terminated or withdrawn. Advaxis, Inc. leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Nov 2022 — Mar 2023 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Apr 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Advaxis, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .